Archives of rheumatology最新文献

{"title":"Erdheim-Chester disease in a psoriatic arthritis patient.","authors":"Elif Altunel Kılınç, Gizem Kırmızıer, Nurdan Yıldırım, Gözde Arslan, Anıl Tombak, Hamide Sayar","doi":"10.46497/ArchRheumatol.2023.10261","DOIUrl":"10.46497/ArchRheumatol.2023.10261","url":null,"abstract":"","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 1","pages":"136-137"},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reliability and validity of the Turkish version of Scleroderma Skin Patient-Reported Outcome in patients with systemic sclerosis.","authors":"Fulden Sari, Zilan Bazancir Apaydin, Hakan Apaydin, Mehmet Kayaalp, Abdulsamet Erden, Serdar Can Güven, Berkan Armağan, Ahmet Omma, Orhan Kucuksahin, Şükran Erten","doi":"10.46497/ArchRheumatol.2023.10183","DOIUrl":"10.46497/ArchRheumatol.2023.10183","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to translate the Scleroderma Skin Patient-Reported Outcome (SSPRO) questionnaire to the Turkish (SSPRO-T) language and to assess its validity and reliability.</p><p><strong>Patients and methods: </strong>Fifty-four systemic sclerosis (SSc) patients (51 females, 3 males; mean age: 49.8±10.4 years; range, 22 to 65 years) participated in the reliability and validity analysis between October 2022 and December 2022. The translation and cross-cultural adaptation of the SSPRO-T was applied in accordance with the procedure described by the Beaton guidelines. The SSPRO-T, the Scleroderma Health Assessment Questionnaire (SHAQ), the Health Assessment Questionnaire Disability Index (HAQ-DI), Skindex-29, and patient global skin severity were conducted in all participants for construct validity. The SSPRO-T was retested to assess its reliability after seven days.</p><p><strong>Results: </strong>The SSPRO-T had a four-factor structure. The total SSPRO-T score and its subgroups correlated positively with SHAQ, HAQ-DI, Skindex-29, and patient global skin severity. The internal consistency and reliability were excellent in overall SSPRO-T and in the subgroups: physical effect, emotional effect, physical limitation, and social effect (Cronbach's α=0.94, 0.80, 0.95, 0.93, and 0.84, respectively). The SSPRO-T had excellent test-retest reliability (r=0.91, p<0.001). In addition, no floor effect or ceiling effect was observed.</p><p><strong>Conclusion: </strong>The SSPRO-T questionnaire is a reliable and valid tool and can be used in research and clinical practice in Turkish patients with SSc.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 1","pages":"52-59"},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does age at disease onset affect the clinical presentation and outcome in children with immunoglobulin A vasculitis?","authors":"Emine Nur Sunar Yayla, Sevcan A Bakkaloğlu","doi":"10.46497/ArchRheumatol.2023.9914","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.9914","url":null,"abstract":"<p><strong>Objectives: </strong>The study aimed to determine whether there is a relationship between the age at diagnosis and the clinical, laboratory, and prognostic features in pediatric immunoglobulin A vasculitis (IgAV) patients.</p><p><strong>Patients and methods: </strong>In this study, 539 pediatric IgAV patients (298 males, 241 females; mean age: 7.74±3.36 years; range, 1 to 17.8 years) were retrospectively evaluated between January 2005 and July 2020. The relationship between clinical findings and age at diagnosis was analyzed by univariate logistic regression analysis. Factors associated with renal involvement, steroid-dependent or refractory disease, and recurrence were examined.</p><p><strong>Results: </strong>The median age of diagnosis was 7.1 (1-17.8) years in all patients. At the time of admission, purpura, abdominal pain, and arthritis were the most common clinical findings. At the time of diagnosis, there was a positive association between age and purpura and an inverse association with the presence of arthritis. There were associations between renal involvement and age at diagnosis (odds ratio=1.22, 95% confidence interval 1.13-1.31, p<0.001), follow-up time (p<0.001), no history of previous infection (p<0.001), and presence of gastrointestinal (GI) involvement (p=0.003). Significant relationships were found between the age at diagnosis, follow-up time, GI involvement, renal involvement, scrotal involvement, the C-reactive protein value at the time of diagnosis, and the presence of steroid-dependent disease. An association was found between recurrence and GI involvement. All refractory patients had renal involvement. Age at diagnosis (p<0.001) and follow-up time (p<0.001) was found to be associated with refractory disease.</p><p><strong>Conclusion: </strong>Age at diagnosis and follow-up time may be associated with renal involvement and refractory and steroid-dependent disease in IgAV. In addition, there may be a relationship between steroid-dependent disease and renal, GI, and scrotal involvement and between GI involvement and recurrence.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"38 4","pages":"633-641"},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10728748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A different presentation of tubulointerstitial nephritis and uveitis syndrome mimicking Sjögren's syndrome.","authors":"Reyhan Yılmaz, Ahmet Murt, Iclal Gurses, Serdal Ugurlu","doi":"10.46497/ArchRheumatol.2023.10042","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.10042","url":null,"abstract":"","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"38 4","pages":"659-661"},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10728746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between levels of serum and urinary B cell-activating factor and systemic lupus erythematosus disease activity.","authors":"Maryam Rezazadeh, Mohammad Hasan Jokar, Seyedeh Mehrnaz Aghili, Zahra Mirfeizi, Mahmoud Mahmoudi, Negar Morovatdar, Kamila Hashemzadeh","doi":"10.46497/ArchRheumatol.2023.9549","DOIUrl":"10.46497/ArchRheumatol.2023.9549","url":null,"abstract":"<p><strong>Objectives: </strong>This study investigated the correlation between serum and urinary B cell-activating factor (BAFF) levels and systemic lupus erythematosus (SLE) disease activity.</p><p><strong>Patients and methods: </strong>This case-control study was conducted with 87 participants between December 2020 and September 2021. Sixty-two SLE patients who fulfilled the eligibility criteria were enrolled. SLE patients were categorized into active (n=34) and inactive (n=28) groups based on their Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores. The control group consisted of 25 healthy subjects. Serum and urine samples were collected for the measurement of BAFF levels. Finally, the relationship between these variables and SLE disease activity was investigated.</p><p><strong>Results: </strong>The mean age of active (SLEDAI-2K >4) and inactive (SLEDAI-2K ≤4) SLE patients and healthy individuals were 32.8±7.8, 32.5±6.8, and 31.7±7.8 years, respectively (p=0.62). The median serum BAFF (s-BAFF) and urinary BAFF (u-BAFF) in active lupus patients (10.4 [2.3] ng/mL and 8.2 [3.7] ng/mL, respectively) were significantly higher than in inactive lupus patients (6 (7.1) ng/mL and 1.7 (4.7) ng/mL, respectively; p<0.001) and the control group (3 (3.7) ng/mL and 1.6 (2.2) ng/mL, respectively; p<0.001). However, s-BAFF (p=0.07) and u-BAFF (p=0.43) did not significantly differ between the inactive group and the control group. A significant positive correlation was observed between s-BAFF (r=0.41 and p=0.001) and u-BAFF (r=0.78 and p<0.001) levels and the SLEDAI-2K score.</p><p><strong>Conclusion: </strong>There is a significant positive correlation between serum and urinary BAFF levels and SLE disease activity. Furthermore, significantly higher levels of s-BAFF and u-BAFF have been observed in patients with active lupus compared to inactive and healthy subjects, indicating a possible role for BAFF in the pathogenesis of SLE disease activity.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"38 3","pages":"429-440"},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138479780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of oligomeric proanthocyanidins on hydroxychloroquine-induced retinopathy as revealed by nationwide medical claim data for South Korea.","authors":"Soyeon Kim, Hyeryeong Nam, Bora Lee, Kyung-Ann Lee, Kyung Seek Choi, Hyun-Sook Kim","doi":"10.46497/ArchRheumatol.2023.9829","DOIUrl":"10.46497/ArchRheumatol.2023.9829","url":null,"abstract":"Although hydroxychloroquine (HCQ) is considered to be safe drug with antiinf lammatory, immunomodulatory, and antithrombotic effects,1,2 rare cases of permanent visual impairment.2,3 The prevalence of HCQ retinopathy is about 7.5% for more than five years, increasing after 20 years.4 Oligomeric proanthocyanidins (OPCs) are antioxidants and rich in a grape seed extract.5-7 The extract is effective in some patients with non-proliferative diabetic retinopathy.8,9 The extract may protect retinal cells by inhibiting the oxidative stressmediated apoptosis mediated by activation of the nuclear factor erythroid 2–related factor 2 (Nrf2) pathway in patients with diabetic retinopathy.9 No study has explored whether the extract may protect against HCQ retinopathy.10","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"38 3","pages":"482-489"},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138479799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aryl hydrocarbon receptor gene expression in ankylosing spondylitis and its correlation with interleukin-17, RAR-related orphan receptor gamma t expression, and disease activity indices.","authors":"Maryam Ahmadi, Narjes Soleimanifar, Abdolrahman Rostamian, Maryam Sadr, Hanieh Mojtahedi, Abeda Mazari, Mohammad Hossein Nicknam, Sara Assadiasl","doi":"10.46497/ArchRheumatol.2023.10203","DOIUrl":"10.46497/ArchRheumatol.2023.10203","url":null,"abstract":"<p><strong>Objectives: </strong>Considering the role of T helper (Th)17 cells in the pathogenesis of ankylosing spondylitis (AS), the aim of this study was to determine the correlation between aryl hydrocarbon receptor (AHR) gene expression and the expression of Th17-related genes including interleukin (IL)-17 and RAR-related orphan receptor gamma t (RORγt) transcription factor.</p><p><strong>Patients and methods: </strong>Thirty patients with AS (26 males, 4 females; mean age: 36.1±8.1 years) and 30 age- and sex-matched healthy individuals (26 males, 4 females; mean age: 36.2±14.6 years) were recruited for the case-control study between June 2021 and January 2022. Ribonucleic acid (RNA) was extracted from peripheral blood cells and expression levels of AHR, IL-17, RORγt, and AHR repressor (AHRR) genes were evaluated using real-time polymerase chain reaction technique. The serum level of IL-17 was evaluated with enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>The results showed a nonsignificant elevation of AHR, IL-17, and RORγt gene expression in the patient group compared to the control. There was a direct correlation between AHR gene expression and IL-17 and RORγt genes and a negative correlation between AHR and AHRR expression. Moreover, AHR gene expression showed a weak correlation with disease activity indices, including Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Metrology Index, Bath Ankylosing Spondylitis Global Score, and Ankylosing Spondylitis Quality of Life. Moreover, the serum level of IL-17 was higher in AS patients compared to the healthy group (p=0.02).</p><p><strong>Conclusion: </strong>Upregulated expression of the AHR gene in ankylosing spondylitis and its correlation with IL-17 and ROR-γ t gene expression suggests that it could be a potential diagnostic and therapeutic target for AS.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 1","pages":"123-132"},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two sisters with one disease: Giant cell arteritis within one family.","authors":"Marko Barešić, Lucija Šimunić, Goran Šukara, Miroslav Mayer, Branimir Anić","doi":"10.46497/ArchRheumatol.2023.10192","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.10192","url":null,"abstract":"","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"38 4","pages":"662-664"},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10728738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evaluation of the burden of multisystem inflammatory syndrome in children on health economics.","authors":"Ezgi Balkarlı, Elif Kıymet, Elif Böncüoğlu, Şahika Şahinkaya, Miray Yılmaz Çelebi, Hurşit Apa, Timur Meşe, Hasan Ağın, Süleyman Nuri Bayram, İlker Devrim","doi":"10.46497/ArchRheumatol.2023.10147","DOIUrl":"10.46497/ArchRheumatol.2023.10147","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to evaluate the diagnostic tests and treatments applied in patients with multisystem inflammatory syndrome in children (MIS-C) and to determine the effect of the disease on health costs.</p><p><strong>Patients and methods: </strong>This retrospective cohort study included 59 MIS-C patients (40 males, 19 females; mean age: 7.7±4.2 years; range, 4 months to 16.5 years) who were admitted and treated between April 1, 2020, and November 1, 2021. Demographic and clinical features with hospital costs and length of stay were retrospectively reviewed from the medical files and computerized system of the hospital. Direct medical care costs of items were calculated with the hospital perspective using a combination of microcosting technique (resource-based accounting method) and hospital list data. Cases were classified as mild, moderate, or severe, and the patients were divided into two groups: the mild group and the moderate-severe group. Classification was determined by the vasoactive inotropic score (VIS), degree of respiratory support, and evidence of organ damage.</p><p><strong>Results: </strong>The mean age of the cases in the mild group was 6.5±3.7 years, and the mean age of the cases in the moderate-severe group was 9.2±4.3 years. Of 59 patients, 19 (32.2%) were followed up in the pediatric intensive care unit. The median duration of hospitalization in the hospital was 8 (interquartile range: 7-12) days. The total cost of the patients hospitalized with the diagnosis of MIS-C during the study period was 849,242.93$, and the mean cost per patient was 14,393.94±9,631.92$. In the distribution of the total cost of hospitalization according to expenses, the highest rate was pharmacy and blood products (51.99%) and IVIG costs (43.99%). While the mean total cost per person was 13,682.87±8,799.63$ in mild cases, it was 16,433.82±9,440.02$ in moderate-severe cases, and no statistically significant relationship was found between the two groups (p>0.05). There was no difference in the mean cost per patient between the cases with and without heart, lung, kidney, or neurologic involvement and advanced respiratory support (p>0.05). There was a strong positive correlation between the total costs and age (r=0.883, n=59, p<0.0001), with increased amount of costs with increased age.</p><p><strong>Conclusion: </strong>In the study, no statistically significant correlation was found between the total cost of per person in the mild group and the moderate-severe group (p>0.05). This finding may be due to the wide use of IVIG in MIS-C treatment, in addition to low transfer rates to pediatric intensive care units due to high-flow nasal cannula usage.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 1","pages":"10-19"},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between Mycoplasma and Kawasaki disease in pediatric patients: An updated systematic review and meta-analysis.","authors":"Min Cheng, Gaihuan Zheng, Lu Gao, Bihong Zhang","doi":"10.46497/ArchRheumatol.2023.10149","DOIUrl":"10.46497/ArchRheumatol.2023.10149","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to clarify the relationship between <i>Mycoplasma pneumoniae (M. pneumoniae)</i> and Kawasaki disease by conducting an updated systemic review and meta-analysis of published studies.</p><p><strong>Materials and methods: </strong>Studies mentioning <i>M. pneumoniae</i> and Kawasaki disease before October 2022 were included in this meta-analysis. The pooled prevalence was calculated, and the log odds ratio in the random effects model was applied to estimate the pooled prevalence of <i>M. pneumoniae</i> infection in pediatric patients with Kawasaki disease. In addition, the clinical parameters, such as hemoglobin and erythrocyte sedimentation rate, were analyzed. Six studies with a total of 1,859 pediatric patients with Kawasaki disease were enrolled. The focused outcome was the pooled prevalence and clinical parameters.</p><p><strong>Results: </strong>The pooled prevalence of <i>M. pneumoniae</i> infection was statistically significant in pediatric patients with Kawasaki disease. In addition, the values of hemoglobin and erythrocyte sedimentation rate were significantly different between <i>M. pneumoniae</i>-infected and non-<i>M. pneumoniae</i>-infected patients with Kawasaki disease. Other clinical parameters were not significantly different between <i>M. pneumoniae</i>-infected and non-<i>M. pneumoniae</i>-infected patients with Kawasaki disease.</p><p><strong>Conclusion: </strong>The results suggest that <i>M. pneumoniae</i> infection is significantly prevalent in pediatric patients with Kawasaki disease. The lower values of hemoglobin and erythrocyte sedimentation rate in <i>M. pneumoniae</i>-infected patients with Kawasaki disease might be needed to investigate further.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 1","pages":"140-148"},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}